Get the Stockscreener App
9.29
8.40%
0.72
After Hours:
9.29
Verastem Inc stock is traded at $9.29, with a volume of 1.94M.
It is up +8.40% in the last 24 hours and down -4.42% over the past month.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
See More
Previous Close:
$8.57
Open:
$8.65
24h Volume:
1.94M
Relative Volume:
0.82
Market Cap:
$571.76M
Revenue:
$3.64M
Net Income/Loss:
$-87.37M
P/E Ratio:
-2.2603
EPS:
-4.11
Net Cash Flow:
$-86.46M
1W Performance:
+7.90%
1M Performance:
-4.42%
6M Performance:
+100.22%
1Y Performance:
+212.79%
1-Day Range:
$8.53
$9.405
1-Week Range:
$8.53
$9.46
52-Week Range:
$2.54
$11.24
Verastem Inc Stock (VSTM) Company Profile
Name
Verastem Inc
Sector
Industry
Phone
(781) 292-4200
Address
117 KENDRICK STREET, NEEDHAM, MA
Compare VSTM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
9.29 | 527.44M | 3.64M | -87.37M | -86.46M | -4.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Initiated | Jefferies | Buy |
| Mar-24-25 | Reiterated | H.C. Wainwright | Buy |
| Dec-31-24 | Reiterated | BTIG Research | Buy |
| Sep-30-24 | Initiated | Guggenheim | Buy |
| Nov-21-23 | Resumed | BTIG Research | Buy |
| Sep-27-23 | Initiated | B. Riley Securities | Buy |
| Jun-15-23 | Upgrade | Mizuho | Neutral → Buy |
| Sep-07-22 | Resumed | Alliance Global Partners | Buy |
| Apr-29-22 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-14-22 | Initiated | RBC Capital Mkts | Outperform |
| Mar-09-22 | Initiated | Truist | Buy |
| Jul-01-21 | Initiated | Alliance Global Partners | Buy |
| May-24-21 | Upgrade | BTIG Research | Neutral → Buy |
| Jun-20-19 | Downgrade | BTIG Research | Buy → Neutral |
| May-10-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-13-18 | Initiated | BTIG Research | Buy |
| May-02-18 | Initiated | Seaport Global Securities | Buy |
| Mar-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Sep-07-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-13-17 | Initiated | Oppenheimer | Outperform |
| Mar-24-17 | Reiterated | H.C. Wainwright | Buy |
| Sep-29-15 | Downgrade | Cantor Fitzgerald | Buy → Hold |
| Sep-29-15 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-29-15 | Downgrade | Jefferies | Buy → Hold |
| Sep-29-15 | Downgrade | Raymond James | Strong Buy → Outperform |
| Sep-28-15 | Downgrade | Mizuho | Buy → Neutral |
| Sep-28-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-09-15 | Initiated | Raymond James | Strong Buy |
| May-12-15 | Reiterated | UBS | Buy |
| Apr-08-15 | Initiated | H.C. Wainwright | Buy |
| Jan-23-15 | Reiterated | ROTH Capital | Buy |
| Jul-08-14 | Resumed | Oppenheimer | Perform |
| Feb-11-14 | Initiated | Mizuho | Buy |
View All
Verastem Inc Stock (VSTM) Latest News
Can Verastem Inc. stock hit record highs againJuly 2025 Price Swings & Capital Efficiency Focused Strategies - newser.com
What momentum indicators show for Verastem Inc. stock2025 Growth vs Value & Technical Pattern Recognition Alerts - newser.com
Volume spikes in Verastem Inc. stock – what they meanWeekly Market Report & Precise Entry and Exit Recommendations - newser.com
Analyzing Verastem Inc. with multi timeframe chartsRisk Management & Smart Swing Trading Techniques - newser.com
How to read the order book for Verastem Inc.July 2025 Reactions & High Yield Stock Recommendations - newser.com
Verastem's (VSTM) Sell (D-) Rating Reaffirmed at Weiss Ratings - MarketBeat
What analysts say about Verastem Inc stockCandlestick Trading Patterns & High Return Stock Picks - earlytimes.in
Using portfolio simulators with Verastem Inc. included2025 Major Catalysts & Fast Entry and Exit Trade Plans - newser.com
Verastem: Navigating Critical Steps In Commercialization And Development(Downgrade) (VSTM) - Seeking Alpha
Verastem (NASDAQ:VSTM) Shares Up 4.9%Still a Buy? - MarketBeat
Verastem Oncology announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Analyzing net buyer seller activity in Verastem Inc.July 2025 Technicals & Daily Entry Point Alerts - newser.com
When is the best time to exit Verastem Inc.Quarterly Earnings Report & Technical Pattern Recognition Alerts - newser.com
Verastem, Inc. (NASDAQ:VSTM) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Verastem, Inc. (NASDAQ:VSTM) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
What sentiment indicators say about Verastem Inc. stockMarket Growth Summary & Real-Time Sentiment Analysis - newser.com
Is Verastem Inc. (2VSA) stock a buy before earnings resultsJuly 2025 Reactions & Consistent Return Strategy Ideas - newser.com
Historical volatility pattern of Verastem Inc. visualizedQuarterly Investment Review & Reliable Breakout Forecasts - newser.com
Verastem (NASDAQ:VSTM) Stock Passes Above 200-Day Moving AverageShould You Sell? - MarketBeat
What analysts say about Verastem Inc 2VSA stockHigh Yield Income Stocks & Explosive Capital Growth - earlytimes.in
Verastem Oncology to Report Q1 Earnings: What's in the Cards? - MSN
Is Verastem Inc a good long term investmentStock Split Announcements & Build Your Portfolio With Our Free Stock Scanner - Early Times
Insiders At Verastem Sold US$783k In Stock, Alluding To Potential Weakness - simplywall.st
Verastem (NASDAQ:VSTM) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Goldman Sachs Group Inc. Has $4.56 Million Stake in Verastem, Inc. $VSTM - MarketBeat
Verastem (NASDAQ:VSTM) Shares Up 5.6%Here's Why - MarketBeat
Risk Recap: How is Verastem Inc managing supply chain issuesJuly 2025 Market Mood & Weekly Chart Analysis and Trade Guides - خودرو بانک
Wall Street Zen Upgrades Verastem (NASDAQ:VSTM) to “Hold” - Defense World
Momentum Shift: Is Verastem Inc forming a double bottomInflation Watch & Real-Time Market Sentiment Alerts - خودرو بانک
Weekly Trades: Is WALD benefiting from interest rate changes2025 Support & Resistance & Safe Capital Investment Plans - khodrobank.com
Can Verastem Inc. hit a new high this monthPortfolio Risk Summary & Real-Time Market Sentiment Reports - newser.com
Verastem Inc. stock trendline breakdownProduct Launch & Weekly High Conviction Ideas - newser.com
Verastem (VSTM) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Gains Report: Is Verastem Inc. stock risky to hold nowMarket Weekly Review & Smart Swing Trading Alerts - خودرو بانک
Verastem (NASDAQ:VSTM) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Insider Selling: Brian Stuglik Sells Shares of Verastem Inc (VST - GuruFocus
Verastem Inc Stock (VSTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Verastem Inc Stock (VSTM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Calkins Daniel | Chief Financial Officer |
Sep 22 '25 |
Sale |
9.08 |
57 |
518 |
109,863 |
| Calkins Daniel | Chief Financial Officer |
Sep 24 '25 |
Sale |
9.23 |
25 |
231 |
109,838 |
| Stuglik Brian M | Director |
Sep 16 '25 |
Sale |
9.99 |
587 |
5,864 |
101,739 |
| Gagnon Robert E. | Director |
Sep 16 '25 |
Sale |
9.99 |
281 |
2,807 |
41,961 |
| Paterson Dan | President and CEO |
Sep 16 '25 |
Sale |
9.99 |
390 |
3,896 |
442,117 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):